1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61AC3F15575814D8885257A6900732795
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/hol-differentiate-the-roles-engage-with-customers-future-trends?opendocument
18
19opendocument
2054.227.157.163
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

Health Outcomes Liaison Excellence: Role Differentiation, Customer Engagement, and Future Trends

ID: 5219


Features:

18 Info Graphics

10 Data Graphics

65+ Metrics

13 Narratives

5 Best Practices


Pages/Slides: 37


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Health Outcomes Liaison Excellence: Role Differentiation, Customer Engagement, and Future Trends"

STUDY OVERVIEW

Concerns about compliance and legal limitations are forcing companies to re-examine how they utilize different emerging educator groups, such as Health Outcome Liaisons (HOLs). In addition, companies are also trying to better differentiate roles of these educator groups and delineate their responsibilities in order to maximize the utility they provide the diverse group of customers they regularly engage.

Best Practices, LLC conducted this study to provide information on how the roles of HOLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the HOL landscape. This research also presents benchmarks and insights around how companies differentiate the roles of HOLs, how the function engages with customers and future trends for the role of HOLs. Biopharmaceutical and medical device executives can use this study to determine the best practices for utilizing HOLs and eliminating unnecessary overlap when engaging internal and external customers.


KEY TOPICS

  • Health Outcome Liaisons: Role Differentiation
  • Health Outcome Liaisons: Customer Engagement
  • Health Outcome Liaisons: Looking Ahead
  • Participant Demographic Data

SAMPLE KEY METRICS
  • Differentiation of HOL/MSL responsibilities
  • HOL/MSL client overlap
  • Top practices for HOL function that are valued most
  • Primary HOL activities and time dedicated to each
  • Initial HOL involvement with drug in development
  • Length of HOL involvement over drug lifecycle
  • Percentage of time HOLs spend in the field
  • Level of involvement with payers for different activities
  • Length of face-to-face visit with thought leaders and payer groups
SAMPLE KEY FINDINGS
  • Decision Makers Will Increasingly Rely on Health Outcomes Data: As health care reform changes take effect, comparative effectiveness and health outcomes data are becoming increasingly important, with some predicting that member outcomes data will eventually be more influential than clinical data when health care leaders are charged with making reimbursement decisions.
  • HOL Roles Are Differentiated from MSLs: Participants take a variety of approaches to differentiating roles of HOLs from Medical Science Liaisons (MSLs), Key Account Managers, and other customer-focused resources. Frequently, companies differentiate HOLs and MSLs by assigning them to different customer groups, with HOLs focused primarily on supporting payers and the Commercial Sales staff that calls on them. MSLs support physicians and the sales reps who see them. HOLs are also defined by their clinical experience and ability to understand and communicate deep clinical knowledge.
METHODOLOGY

Best Practices, LLC engaged 23 HOL program leaders from 19 different pharmaceutical and medical device companies. In addition, deep-dive interviews were conducted with five participating companies to gather additional insights.

Industries Profiled:
Biotech; Pharmaceutical; Medical Device; Health Care; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Becton Dickinson; Boehringer Ingelheim; Cubist; Daiichi-Sankyo; Endo; Fresenius; Genentech; GlaxoSmithKline; Janssen; Medivation; Merck & Co.; Merck Serono; Pacira; Peloton; Sanofi; Sanofi Pasteur; Shire; Teva


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.